CAMP4 Therapeutics completes successful IPO, establishes collaboration with BioMarin, reports $13.5M net loss.
From GlobeNewswire: 2024-11-21 16:05:00 CAMP4 Therapeutics completed an IPO, raising $82.1M. Phase 1 study of CMP-CPS-001 is progressing, with safety
